Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874518 | 0.75 | — | — | |
| SCHEMBL3381845 | 0.71 | SLC7A5 (0.39) | SLC7A5USP2SLCO1B1LMNASLC1A3 | |
| SCHEMBL583793 | 0.69 | SMN1; SMN2 (0.46) | SLC7A5USP2SLCO1B1LMNASLC1A3 | |
| SCHEMBL583792 | 0.69 | SMN1; SMN2 (0.46) | SLC7A5USP2SLCO1B1LMNASLC1A3 | |
| SCHEMBL10656950 | 0.65 | GSR (0.48) | ARG1ARG2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10655128 | 0.65 | GSR (0.48) | ARG1ARG2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3875730 | 0.64 | SLC7A5 (0.46) | SLC7A5USP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL8976692 | 0.63 | — | — | |
| SCHEMBL3875738 | 0.63 | — | — | |
| SCHEMBL3875735 | 0.62 | SLC7A5 (0.39) | SLC7A5USP2SLCO1B1LMNASLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | claimed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | claimed |
| CN-111698906-A | Molecules having pesticidal utility, compositions and pest control methods related thereto | 美国陶氏益农公司 | 2020-09-22 | — | — | CN | disclosed |
| WO-2010017405-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | disclosed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287866-A1 | Methods and compositions for the treatment of pain | ACHE, S100P, P2RX3 | SLC7A5 4883/4885GLO1 2918/4885ARG1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.